原始出處紀錄
重大申請已送件
Monopar 啟動 ALXN1840 治療威爾森氏症的 NDA 滾動提交
Monopar 已開始向 FDA 提交 ALXN1840（tiomolibdate choline）治療威爾森氏症的 NDA 滾動申請。提交現已生效，資產從提交前階段進入正式審查途徑。目前尚未公布 PDUFA 日期或受理決定。
關鍵事實
- 申報時間
- 2026年7月22日 下午12:00
- 事件
- 申請已送件
- 方向
- 正面
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
mnpr20260721_8k.htm false 0001645469 0001645469 2026-07-22 2026-07-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2026 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1000 Skokie Blvd., Suite 350 , Wilmette , IL 60091 (Address of principal executive offices) (Zip Code) ( 847 ) 388-0349 Registrant’s telephone number, including area code N/A (Former name or former address, if changed since last report) Securities regi